MagForce AG (MGFRF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist MagForce AG (MGFRF) ein Healthcare-Unternehmen mit einer Bewertung von 0. Bewertet mit 38/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 18. März 2026MagForce AG (MGFRF) Gesundheitswesen & Pipeline-Uebersicht
MagForce AG, a German nanotechnology company, focuses on cancer therapy through its NanoTherm system, which uses magnetic hyperthermia to treat brain tumors. With a presence in Germany and Poland, the company offers a comprehensive treatment approach including planning software and magnetic field generators, operating in a competitive medical device landscape.
Investmentthese
MagForce AG presents a high-risk, high-reward investment opportunity in the niche area of nanotechnology-based cancer therapy. The company's NanoTherm therapy offers a novel approach to treating brain tumors, but its financial performance is currently weak, reflected in a negative profit margin of -3004.2% and a high P/E ratio of -329.76. Growth catalysts include expanding adoption of NanoTherm in Germany and Poland, securing regulatory approvals in new markets, and demonstrating clinical efficacy through ongoing research. The company's success hinges on its ability to commercialize its technology, achieve profitability, and navigate the competitive landscape. Investors should carefully consider the company's financial position, market adoption rate, and potential regulatory hurdles.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- MagForce AG operates in the nanotechnology-based cancer therapy field, offering NanoTherm for brain tumor treatment.
- The company's NanoTherm therapy is complemented by NanoPlan software for treatment planning and NanoActivator for magnetic field generation.
- MagForce AG's market capitalization is approximately $0.00 billion, indicating its small size within the medical device industry.
- The company's negative profit margin of -3004.2% reflects its current lack of profitability.
- MagForce AG's stock exhibits high volatility with a beta of 3.02, suggesting significant price fluctuations relative to the market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Innovative NanoTherm technology for targeted cancer therapy.
- Comprehensive treatment system including software and hardware.
- Established presence in Germany and Poland.
- Potential for expansion into new markets and applications.
Schwaechen
- Limited financial resources and profitability.
- Small market capitalization and low trading volume.
- Dependence on regulatory approvals for market expansion.
- Competition from established medical device companies.
Katalysatoren
- Upcoming: Potential regulatory approvals for NanoTherm therapy in new markets.
- Ongoing: Continued clinical trials demonstrating the efficacy of NanoTherm.
- Ongoing: Strategic partnerships with hospitals and cancer centers to expand adoption.
Risiken
- Potential: Regulatory hurdles and delays in obtaining approvals for NanoTherm.
- Potential: Competition from established medical device companies and alternative cancer therapies.
- Ongoing: Limited financial resources and profitability.
- Ongoing: Dependence on a single product (NanoTherm) for revenue generation.
- Potential: Negative publicity or safety concerns regarding NanoTherm therapy.
Wachstumschancen
- Expansion into New Geographic Markets: MagForce AG has the opportunity to expand its operations beyond Germany and Poland into other European countries and potentially the United States. This expansion would require regulatory approvals and significant investment in marketing and sales infrastructure. The global market for cancer therapy is substantial, offering significant revenue potential if MagForce AG can successfully navigate regulatory hurdles and establish a presence in new markets. Timeline: 2-5 years.
- Development of New Applications for NanoTherm Technology: MagForce AG can explore the use of its NanoTherm technology for the treatment of other types of cancer beyond brain tumors. This would involve conducting clinical trials and obtaining regulatory approvals for new indications. Expanding the application of NanoTherm could significantly increase the company's market opportunity and revenue potential. The timeline for developing new applications is dependent on the clinical trial process and regulatory approval timelines. Timeline: 3-7 years.
- Strategic Partnerships with Hospitals and Cancer Centers: MagForce AG can form strategic partnerships with hospitals and cancer centers to promote the adoption of NanoTherm therapy. These partnerships could involve training healthcare professionals, providing technical support, and collaborating on research projects. Building strong relationships with key stakeholders in the healthcare industry is crucial for driving the commercial success of NanoTherm. Timeline: Ongoing.
- Advancements in Nanoparticle Technology: Continued research and development in nanoparticle technology could lead to improvements in the efficacy and safety of NanoTherm therapy. This could involve developing nanoparticles with enhanced targeting capabilities, improved heat generation properties, or reduced toxicity. Technological advancements could strengthen MagForce AG's competitive position and attract more patients to its therapy. Timeline: Ongoing.
- Increased Awareness and Education: MagForce AG can invest in marketing and educational initiatives to raise awareness of NanoTherm therapy among patients, physicians, and the general public. This could involve publishing scientific articles, presenting at medical conferences, and developing patient education materials. Increased awareness could drive demand for NanoTherm and accelerate its adoption in the market. Timeline: Ongoing.
Chancen
- Expansion into new geographic markets.
- Development of new applications for NanoTherm technology.
- Strategic partnerships with hospitals and cancer centers.
- Advancements in nanoparticle technology.
Risiken
- Regulatory hurdles and delays.
- Competition from alternative cancer therapies.
- Technological obsolescence.
- Economic downturns and healthcare spending cuts.
Wettbewerbsvorteile
- Proprietary NanoTherm technology protected by patents.
- Specialized expertise in nanotechnology-based cancer therapy.
- Established presence in Germany and Poland.
- Integrated treatment system including therapy, software, and hardware.
Ueber MGFRF
Founded in 1997 and headquartered in Berlin, Germany, MagForce AG is a medical device company operating in the niche field of nanotechnology-based cancer therapy. The company's core offering is NanoTherm, a therapy designed for the treatment of brain tumors. This innovative approach utilizes magnetic hyperthermia to selectively heat and destroy cancer cells while minimizing damage to surrounding healthy tissue. Beyond the NanoTherm therapy itself, MagForce AG provides a comprehensive treatment solution. NanoPlan software assists physicians in developing personalized treatment plans, optimizing the effectiveness of the NanoTherm therapy for each patient. The NanoActivator, a magnetic field generator, delivers the controlled magnetic field necessary to activate the nanoparticles within the tumor. MagForce AG currently operates in Germany and Poland, focusing on expanding the adoption of NanoTherm therapy within these markets. The company faces competition from established medical device companies and other emerging cancer therapy technologies. With a small team of 33 employees, MagForce AG is focused on advancing its technology and expanding its market reach within the evolving landscape of cancer treatment.
Was das Unternehmen tut
- Develops NanoTherm, a nanotechnology-based therapy for treating brain tumors.
- Offers NanoPlan, a software solution for treatment planning.
- Manufactures NanoActivator, a magnetic field generator used in NanoTherm therapy.
- Provides a comprehensive treatment system for magnetic hyperthermia cancer therapy.
- Focuses on targeted cancer treatment using nanotechnology.
- Operates primarily in Germany and Poland.
Geschaeftsmodell
- Sells NanoTherm therapy as a treatment option for brain tumors.
- Generates revenue from the sale of NanoPlan software licenses.
- Derives income from the sale of NanoActivator magnetic field generators.
- Partners with hospitals and clinics to offer NanoTherm therapy.
Branchenkontext
MagForce AG operates within the medical device industry, specifically targeting the cancer therapy market. The industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. The global cancer therapy market is projected to reach billions of dollars by 2026, driven by an aging population and increasing cancer incidence rates. MagForce AG's nanotechnology-based approach offers a differentiated solution, but it faces competition from established players and alternative treatment modalities. Competitors include companies like ACORQ, AHPIQ, CHCR, GDBYF, and GENN, which are developing and marketing various cancer therapies and medical devices.
Wichtige Kunden
- Hospitals and clinics specializing in cancer treatment.
- Neurosurgeons and oncologists treating brain tumor patients.
- Patients diagnosed with brain tumors who are candidates for NanoTherm therapy.
- Medical centers seeking innovative cancer treatment solutions.
Finanzdaten
Chart & Info
MagForce AG (MGFRF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer MGFRF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer MGFRF.
Kursziele
Wall-Street-Kurszielanalyse fuer MGFRF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von MGFRF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Benjamin J. Lipps
Unknown
Information on Benjamin J. Lipps's background is not available in the provided data. Without additional source material, a detailed career history, education, and previous roles cannot be accurately presented. His professional experience prior to managing MagForce AG remains unknown.
Erfolgsbilanz: Information on Benjamin J. Lipps's track record is not available in the provided data. Specific achievements, strategic decisions, and company milestones under his leadership cannot be accurately assessed without additional source material. His impact on MagForce AG's performance remains unknown.
MGFRF OTC-Marktinformationen
The OTC Other tier, where MagForce AG trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial reporting requirements, meaning they may not be subject to the same level of scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This lack of regulation can lead to increased risks for investors due to the potential for fraud and limited information availability. Companies in this tier may be distressed, early-stage ventures, or foreign companies with limited U.S. presence.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases the risk of investing in MGFRF.
- Low trading volume can lead to price volatility and difficulty in buying or selling shares.
- The OTC Other tier carries a higher risk of fraud and manipulation compared to major exchanges.
- The company's financial stability and long-term viability may be uncertain.
- Lack of regulatory oversight increases the potential for mismanagement and inadequate corporate governance.
- Verify the company's registration and legal standing.
- Obtain and review any available financial statements, even if limited.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor before investing.
- Determine if the company has a history of regulatory issues.
- The company has been in operation since 1997.
- MagForce AG has developed a proprietary technology (NanoTherm) for cancer therapy.
- The company has a presence in Germany and Poland.
- The company's website and marketing materials appear professional.
- The company has a small team of 33 employees.
MGFRF Healthcare Aktien-FAQ
What are the key factors to evaluate for MGFRF?
MagForce AG (MGFRF) currently holds an AI score of 38/100, indicating low score. Key strength: Innovative NanoTherm technology for targeted cancer therapy.. Primary risk to monitor: Potential: Regulatory hurdles and delays in obtaining approvals for NanoTherm.. This is not financial advice.
How frequently does MGFRF data refresh on this page?
MGFRF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MGFRF's recent stock price performance?
Recent price movement in MagForce AG (MGFRF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative NanoTherm technology for targeted cancer therapy.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MGFRF overvalued or undervalued right now?
Determining whether MagForce AG (MGFRF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying MGFRF?
Before investing in MagForce AG (MGFRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MGFRF to a portfolio?
Potential reasons to consider MagForce AG (MGFRF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Innovative NanoTherm technology for targeted cancer therapy.. Additionally: Comprehensive treatment system including software and hardware.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of MGFRF?
Yes, most major brokerages offer fractional shares of MagForce AG (MGFRF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track MGFRF's earnings and financial reports?
MagForce AG (MGFRF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for MGFRF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on limited data available.
- OTC market data may be less reliable than major exchanges.
- AI analysis pending for MGFRF.